A new intranasal therapy (MP29‐02*) is more effective than current firstline therapy regardless of season, symptom or severity. Issue 4 (26th June 2015) - Bachert, Claus; Fokkens, Wytske; Hellings, Peter; Scadding, Glenis; Munzel, Ullrich; Mullol, Joaquim